cmAngio® vs WellDoc BlueStar
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your healthcare facility aims to enhance cardiovascular risk assessment for women by leveraging existing mammography data. This AI-powered tool allows for the early detection and visualization of Breast Arterial Calcifications (BAC) without additional procedures, providing valuable insights for proactive patient care and risk stratification.
View cmAngio® →Choose WellDoc BlueStar if…
Choose WellDoc BlueStar if your organization seeks to empower patients with chronic cardiometabolic conditions through personalized, AI-driven digital health management. This solution offers continuous coaching, integrates with various connected devices, and provides actionable insights to help patients manage conditions like diabetes, hypertension, and heart failure effectively.
View WellDoc BlueStar →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | WellDoc BlueStar |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Mobile app, web-based HCP software, and integration with existing systems. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae is designed for seamless integration into existing radiology workflows, boasting quick installation in under an hour and compatibility with any DICOM-compliant viewer. This minimizes disruption for clinical users and IT departments. While WellDoc BlueStar offers a mobile app for patients, the complexity of managing multiple chronic conditions and device integrations could present usability challenges for some users.
Clinical Value
WellDoc BlueStarWellDoc BlueStar offers comprehensive, AI-powered chronic disease management across multiple conditions, including personalized coaching and insulin dose recommendations, directly impacting patient management and potentially improving outcomes for complex conditions. cmAngiou00ae provides valuable early cardiovascular risk assessment by detecting Breast Arterial Calcifications on mammograms, but its impact is more focused on risk identification rather than direct ongoing disease management.
Pricing & Value
cmAngio®Both tools have opaque enterprise pricing, requiring direct contact with the vendor for details. However, cmAngiou00ae explicitly mentions 'Limited-time offers for no-cost implementation and service may be available,' which could provide significant upfront value for adopting institutions. WellDoc BlueStar's enterprise pricing is paid by health plans, systems, or employers, indicating value at an organizational level without specific cost-saving incentives mentioned.
Enterprise Readiness
WellDoc BlueStarWellDoc BlueStar explicitly confirms having a Business Associate Agreement (BAA) and its business model directly targets health plans, systems, and employers for population health management, demonstrating clear suitability for large-scale deployment. While cmAngiou00ae is FDA-cleared, HIPAA-compliant, and cloud-based, it requires contacting the vendor for BAA details, making its enterprise readiness slightly less transparent in comparison.
Innovation
cmAngio®cmAngiou00ae demonstrates significant innovation by repurposing existing mammography data to detect Breast Arterial Calcifications for cardiovascular risk assessment, extracting new clinical value from a routine screening without additional procedures. WellDoc BlueStar's AI-driven personalized coaching and multi-condition support are also innovative, but cmAngio's approach of deriving novel insights from existing, widely performed diagnostic tests stands out.
Support & Docs
WellDoc BlueStarWellDoc BlueStar provides more explicit and detailed support mechanisms, including a dedicated customer care team with a phone number and operating hours, downloadable PDF information for users, and a care team portal with SMARTVisit reports. While cmAngiou00ae mentions an 'Operator's Manual,' the breadth of documented support for WellDoc BlueStar is more comprehensive.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | WellDoc BlueStar |
|---|---|---|
| Name | cmAngiou00ae | WellDoc BlueStar |
| Company | CureMetrix | WellDoc |
| Primary Purpose | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared, AI-powered digital health solution for chronic disease management, offering personalized coaching and insights for conditions like diabetes, hypertension, and heart failure. |
| Key Functionality | AI-based detection of Breast Arterial Calcifications (BAC) on FFDM and DBT exams, visualization of BAC location, compatible with DICOM-compliant viewers, adjustable operating point. | AI-driven personalized coaching, multi-condition support (diabetes, hypertension, heart failure, weight management, behavioral health), integration with connected devices, insulin dose recommendations, care team portal. |
| Categories | Cardiology AI, OB/GYN AI, Radiology & Imaging AI | Cardiology AI, Endocrinology & Metabolic AI, Patient Engagement & Education |
| Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology, Endocrinology, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and WellDoc BlueStar.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or WellDoc BlueStar
Backers
Who funded each tool's parent company.